Edinburgh Molecular Imaging develops systemic radiotherapy targeting c-Met, a receptor implicated in various cancers. Their technology aims to enhance treatment efficacy across multiple cancer types by specifically targeting tumor cells, potentially improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers express c-Met, a receptor tyrosine kinase that promotes tumor growth, metastasis, and angiogenesis. Systemic radiotherapies often lack specificity, leading to off-target effects and limiting the radiation dose that can be safely delivered to the tumor. This can reduce treatment efficacy and increase toxicity for patients.
Solution
Edinburgh Molecular Imaging is developing targeted systemic radiotherapy agents that selectively bind to c-Met, a receptor overexpressed in a variety of cancers. By targeting c-Met, the company aims to deliver radiation directly to tumor cells while sparing healthy tissue, potentially improving treatment efficacy and reducing side effects. This approach seeks to enhance the therapeutic window for radiotherapy across multiple cancer types.
Target Audience
The primary target audience includes oncology researchers, clinicians, and pharmaceutical companies focused on developing and improving cancer treatment options.
Features
- c-Met-targeted radiopharmaceutical agents for systemic administration
- Selective binding to c-Met expressing tumor cells
- Enhanced radiation delivery to the tumor microenvironment
- Potential for improved efficacy and reduced off-target toxicity compared to traditional radiotherapy